Developing a long-acting injectable (LAI) involves translating the properties of an active pharmaceutical ingredient (API) into a dosage form capable of sustained, reproducible drug release. This requires coordinated decisions across formulation design, polymer selection, analytical testing and manufacturing. A promising release profile alone is not enough: the formulation must also retain the required API quality attributes and remain suitable for further development and scale-up. Although every molecule presents different challenges, long-acting injectable programs generally progress through a series of connected development activities. Understanding how these activities influence one another helps teams identify technical risks before committing to a particular formulation or manufacturing process. Where does long-acting injectable development begin? The starting point for long-acting injectable development is the target product profile (TPP). This defines the intended characteristics of the product, including the route of administration, dose, desired release duration and relevant quality requirements. These objectives establish the framework within which formulation options can be evaluated. The development team must then determine whether the API’s physicochemical properties are compatible with the intended delivery approach. Molecular size, solubility, hydrophobicity, stability and sensitivity to processing conditions may all influence the available formulation options. For peptides and biologics, maintaining molecular integrity during processing and release is particularly important. The required API dose and availability of material for experimental work also affect how the initial development program is designed. The main stages of long-acting injectable development LAI development is rarely a strictly linear process. Results from analytical testing may require changes to the polymer composition, while manufacturing experiments can reveal limitations that were not apparent during early formulation screening. The following stages provide a practical overview of how a development program may progress. Development stage Main activities Expected outcome 1. API characterization Assess molecular properties, stability, solubility and dose requirements. Initial understanding of formulation constraints and technical risks. 2. Feasibility assessment Evaluate potential delivery systems and conduct preliminary formulation experiments. Evidence supporting further investigation of selected formulation approaches. 3. Formulation development Screen polymer compositions, drug loading and formulation parameters. Candidate formulations with promising quality attributes and release behavior. 4. Analytical development Establish methods to assess API integrity, drug content and release characteristics. Analytical evidence for comparing formulations and guiding optimization. 5. Process development Investigate manufacturing parameters, reproducibility and scale-up requirements. A better-defined manufacturing process and understanding of critical parameters. 6. Transfer and manufacturing preparation Document formulation knowledge, process controls and quality requirements. A development package supporting the appropriate next manufacturing stage. Evaluating API feasibility before formulation selection Early feasibility work determines whether a proposed long-acting approach is technically realistic for the molecule and target product profile. Rather than attempting to optimize every formulation characteristic immediately, the initial experiments should address the uncertainties most likely to affect further development. For example, a peptide may be compatible with a particular polymer matrix but require further investigation to determine whether sufficient drug loading and the intended release duration can be achieved together. A biologic may require additional analytical work to assess molecular integrity after processing and during release testing. The outcome of feasibility work is not necessarily a final formulation. It is an evidence-based assessment of which approaches warrant further development, which constraints remain unresolved and what additional experiments are required. Developing and optimizing the formulation Once an appropriate delivery approach has been identified, formulation development focuses on refining the relationship between the API, delivery matrix and intended release profile. For polymer-based systems, development may involve evaluating different polymer grades, adjusting drug loading or changing formulation and processing parameters. These changes can influence water uptake, swelling, diffusion, polymer degradation and the physical characteristics of the dosage form. Formulation optimization therefore involves balancing multiple requirements rather than maximizing one property. Increasing drug loading, for example, may affect the internal structure of a microsphere formulation and alter its release behavior. The significance of such changes must be established experimentally for the specific API and dosage form. Understanding the main challenges in long-acting injectable formulation development is particularly important when changes intended to improve release behavior also affect API stability or manufacturing reproducibility. Using analytical testing to guide development Analytical development provides the information needed to determine whether a formulation is performing as intended. Depending on the dosage form, this may include testing API content, molecular integrity, release behavior, residual solvents and relevant physical characteristics. Release testing is especially important because a long-acting formulation must be evaluated over a period appropriate to its intended performance. Analytical methods should be capable of distinguishing meaningful differences between candidate formulations and identifying changes that require further investigation. For peptide and biologic formulations, analytical assessment may also need to address aggregation, fragmentation or other changes in molecular integrity. The relevant methods depend on the molecule, formulation and development stage. Analytical work is therefore not simply a final quality check. It informs formulation decisions throughout development and helps establish the evidence needed for subsequent process optimization. Developing a reproducible manufacturing process A formulation that performs well in laboratory experiments must also be manufactured consistently. Changes in mixing conditions, equipment, batch size or processing time can influence the physical properties of a long-acting dosage form and, consequently, its release behavior. During process development, relevant manufacturing parameters are investigated to understand their effect on product quality. For microspheres, these may include parameters affecting particle formation and size distribution. For gels or in situ forming depots, viscosity and formulation handling may be more relevant. These differences make it important to consider the manufacturing requirements of the selected dosage form rather than applying a single process strategy to every long-acting technology. Evaluating scalability during development can identify potential limitations before a formulation progresses toward larger-scale manufacturing. The aim is to develop the formulation and its manufacturing process as connected elements of the same program. Preparing for technology transfer and manufacturing As development progresses, formulation and process knowledge must be documented so that the product can be manufactured under the requirements appropriate to its next development stage. Technology transfer may involve documenting the selected formulation, manufacturing instructions, analytical methods, critical process parameters and relevant quality controls. The level of documentation and process understanding required depends on the intended manufacturing activity. Innocore supports this transition through its formulation, analytical and process development capabilities, alongside its broader CDMO services. Depending on the program, development activities may connect with manufacturing of material for nonclinical studies or preparation for GMP manufacturing. Manufacturing readiness is therefore considered throughout development, rather than only after a formulation has been finalized. How long does long-acting injectable development take? There is no standard timeline for developing a long-acting injectable. The duration depends on the molecule, target product profile, formulation complexity, availability of API material and the analytical work required to evaluate candidate formulations. INITIAL FEASIBILITY PROJECT Approximately 6 months At Innocore, an initial feasibility project may take approximately six months as an indication, although the actual scope and timeline are determined for each program. Feasibility work represents an early development stage and should not be confused with the complete timeline required for clinical development or commercialization. Programs involving structurally complex biologics, demanding release requirements or substantial process development may require additional experimental work. Development planning should therefore reflect the specific technical uncertainties of the product. Frequently asked questions about long-acting injectable development What is the first step in developing a long-acting injectable? Development generally begins by defining the target product profile and assessing the API’s relevant physicochemical properties. These establish the requirements and constraints used to evaluate potential formulation approaches. Is feasibility testing the same as formulation development? No. Feasibility testing investigates whether a proposed formulation approach is technically realistic. Formulation development builds on those findings by refining the composition, manufacturing parameters and quality attributes of promising candidates. Why is analytical development important for long-acting injectables? Analytical methods are needed to evaluate API integrity, drug content, release behavior and other relevant quality attributes. They provide evidence for comparing formulations and understanding the effects of development changes. When should scale-up be considered? Scalability should be considered during early formulation and process development. Manufacturing constraints identified at laboratory scale can influence the selection and optimization of the delivery system. Does every long-acting injectable follow the same development process? No. Development activities depend on the API, dosage form, target product profile and intended manufacturing stage. Microspheres, implants, gels and in situ forming depots may require different formulation methods, analytical approaches and manufacturing processes. Discuss your long-acting injectable development program Developing a long-acting injectable requires an integrated approach in which API properties, formulation design, analytical evidence and manufacturing requirements are considered together. Innocore supports pharmaceutical and biotechnology companies through these activities, with particular expertise in polymer-based formulations for peptides and biologics. Contact Innocore to discuss the development requirements and technical feasibility of a long-acting formulation for your API. Contact Innocore